Arylamine N-acetyltransferases: From Structure to Function

REFERENCES

• Adam P. J., Berry J., Loader J. A., Tyson K. L., Craggs G., Smith P., De Belin J., Steers G., Pezzerella F., Sachsenmeir K. F., Stamps A. C., Herath A., Sim E., O'Hare M. J., Harris A. L., Terrett J. A. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol. Cancer Res. 2003; 1: 826–835
   PubMed Web of Science ®Google Scholar
• Anderton M. C., Bhakta S., Besra G. S., Jeavons P., Eltis L. D., Sim E. Characterisation of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG. Mol. Microbiol. 2006; 59: 181–192
   PubMed Web of Science ®Google Scholar
• Barker D. F., Husain A., Neale J. R., Martini B. D., Zhang X., Doll M. A., States J. C., Hein D. W. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet. Genomics 2006; 16: 515–525
   PubMed Web of Science ®Google Scholar
• Bennett E. J., Bence N. F., Jayakumar R., Kopito R. R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 2005; 17: 351–365
   PubMed Web of Science ®Google Scholar
• Ben-Zvi A., De Los Rios P., Dietler G., Goloubinoff P. Active solubilization and refolding of stable protein aggregates by cooperative unfolding action of individual hsp70 chaperones. J. Biol. Chem. 2004; 279: 37298–37303
   PubMed Web of Science ®Google Scholar
• Bhakta S., Besra G. S., Upton A. M., Parish T., Sholto-Douglas-Vernon C., Gibson K. J. C., Knutton S., Gordon S., DaSilva R., Sim E. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J. Exp. Med. 2004; 99: 1191–1199
   Web of Science ®Google Scholar
• Bièche I., Girault I., Urbain E., Tozlu S., Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004; 6: 252–263
   PubMed Web of Science ®Google Scholar
• Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA 1991; 88: 5237–5241
   PubMed Web of Science ®Google Scholar
• Blum M., Grant D. M., McBride W., Heim M., Meyer U. A. Human N-acetyltransferase genes: Isolation, chromosomal localisation and functional expression. DNA Cell Biol. 1990; 9: 193–203
   PubMed Web of Science ®Google Scholar
• Boukouvala S., Fakis G. Arylamine N-acetyltransferases: What we learn from genes and genomes. Drug Metab. Rev. 2005; 37: 511–564
   PubMed Web of Science ®Google Scholar
• Boukouvala S., Price N., Plant K. E., Sim E. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolising enzyme arylamine N-acetyltransferase type 2 in mice. Biochem. J. 2003; 375: 593–602
   PubMed Web of Science ®Google Scholar
• Boukouvala S., Price N., Sim E. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 2002; 12: 385–394
   PubMedGoogle Scholar
• Boukouvala S., Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin. Pharmacol. Toxicol. 2005; 96: 343–351
   PubMed Web of Science ®Google Scholar
• Boukouvala S., Westwood I. M., Butcher N. J., Fakis G. Current trends in NAT research arising from the 2007 International Workshop on the Arylamine N-acetyltransferases. Pharmacogenomics 2008; 9: 765–771
   PubMed Web of Science ®Google Scholar
• Brockmöller J., Cascorbi I., Kerb R., Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996; 56: 3915–3925
   PubMed Web of Science ®Google Scholar
• Brooke E. W., Davies S. G., Mulvaney A. W., Pompeo F., Sim E., Vickers R. J. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. Chem. 2003; 11: 1227–1234
   PubMed Web of Science ®Google Scholar
• Butcher N. J., Arulpragasam A., Goh H. L., Davey T., Minchin R. F. Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5’-UTR splice variants with altered translational activities. Biochem. J. 2005; 387: 119–127
   PubMed Web of Science ®Google Scholar
• Butcher N. J., Arulpragasam A., Minchin R. F. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 2004; 279: 22131–22137
   PubMed Web of Science ®Google Scholar
• Butcher N. J., Arulpragasam A., Pope C., Minchin R. F. Identification of a minimal promoter sequence for the human N-acetyltransferase type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem. J. 2003; 376: 441–448
   PubMed Web of Science ®Google Scholar
• Butcher N. J., Boukouvala S., Sim E., Minchin R. F. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002; 2: 30–42
   PubMedGoogle Scholar
• Butcher N. J., Tetlow N. L., Cheung C., Broadhurst G. M., Minchin R. F. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res. 2007; 67: 85–92
   PubMed Web of Science ®Google Scholar
• Cao W., Chau B., Hunter R., Strnatka D., McQueenm C. A., Erickson R. P. Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J. 2005; 5: 255–261
   PubMed Web of Science ®Google Scholar
• Carmichael S. L., Shaw G. M., Yang W., Iovannisci D. M., Lammer E. Risk of limb deficiency defects associated with NAT1, NAT2, GSTM1, and NOS3 genetic variants, maternal smoking and vitamin supplement intake. Am. J. Med. Genet. 2006; 140A: 1915–1922
   Web of Science ®Google Scholar
• Chuang J. Y., Wang Y. T., Yeh S. H., Liu Y. W., Chang W. C., Hung J. J. Phosphorylation by JNK1 Regulates the Stability of Transcription Factor Sp1 during Mitosis. Mol. Biol. Cell. 2008
   PubMed Web of Science ®Google Scholar
• Chung J. G., Levy G. N., Weber W. W. Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in the tissues of C57BL/6J rapid and B6.A-NatS slow acetylator congenic mice. Drug Metab. Dispos. 1993; 21: 1057–1063
   PubMed Web of Science ®Google Scholar
• Ciechanover A., Finley D., Varshavsky A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 1984; 37: 57–66
   PubMed Web of Science ®Google Scholar
• Conaway R. C., Brower C. S., Conaway J. W. Emerging roles of ubiquitin in transcription regulation. Science 2002; 296: 1254–1258
   PubMed Web of Science ®Google Scholar
• Cornish V. A., Pinter K., Boukouvala S., Johnson N., Labrousse C., Payton M., Priddle H., Smith A. J., Sim E. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. 2003; 3: 169–177
   PubMed Web of Science ®Google Scholar
• De Los Rios P., Ben-Zvi A., Slutsky O., Azem A., Goloubinoff P. Hsp70 chaperones accelerate protein translocation and the unfolding of stable protein aggregates by entropic pulling. Proc Natl Acad Sci USA 2006; 103: 6166–6171
   PubMed Web of Science ®Google Scholar
• Deloménie C., Fouix S., Longuemaux S., Brahimi N., Bizet C., Picard B., Denamur E., Dupret J. M. Identification and functional characterisation of arylamine N-acetyltransferases in eubacteria: Evidence for highly selective acetylation of 5-aminosalicylic acid. J. Bacteriol. 2001; 183: 3417–3427
   PubMed Web of Science ®Google Scholar
• Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A. L., Klijn J. G., Foekens J.A., Cardoso F., Piccart M. J., Buyse M., Sotiriou C., TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007; 13: 3207–3214
   PubMed Web of Science ®Google Scholar
• Doll M. A., Hein D. W. Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Pharmacogenetics 1995; 5: 247–251
   PubMedGoogle Scholar
• Dunning A. M., Healey C. S., Pharoah P. D. P., Teare M. D., Ponder B. A. J., Easton D. F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 843–854
   PubMed Web of Science ®Google Scholar
• Erickson R. P., Cao W., Acuña D. K., Strnatka D. W., Hunter R. J., Chau B. T., Wakefield L. V., Sim E., McQueen C. A. Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts. Mol. Reprod. Dev 2008, in press.
   PubMed Web of Science ®Google Scholar
• Estrada-Rodgers L., Levy G. N., Weber W. W. Characterisation of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expression 1998a; 7: 13–24
   PubMed Web of Science ®Google Scholar
• Estrada-Rodgers L., Levy G. N., Weber W. W. Substrate selectivity of mouse N-acetyltransferase 1, 2, and 3 expressed in COS-1 cells. Drug Metab.Dispos. 1998b; 26: 502–505
   PubMed Web of Science ®Google Scholar
• Evans D. A., White T. A. Human acetylation polymorphism. J. Lab. Clin. Med. 1964; 63: 394–403
   PubMed Web of Science ®Google Scholar
• Fakis G., Boukouvala S., Buckle V., Payton M., Denning C., Sim E. Chromosomal localisation and mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: Identification of a novel upstream non-coding exon for murine Nat2. Cytogenet. Cell Genet. 2000; 90: 134–138
   PubMedGoogle Scholar
• Fakis G., Boukouvala S., Kawamura A., Kennedy S. Description of a novel polymorphic gene encoding for arylamine N-acetyltransferase in the rhesus macaque (Macaca mulatta), a model animal for endometriosis. Pharmacogenet. Genomics 2007; 17: 181–188
   PubMed Web of Science ®Google Scholar
• Ferguson R. J., Doll M. A., Rustan T. D., Hein D. W. Cloning, expression and functional characterisation of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the Syrian hamster. Pharmacogenetics 1996; 6: 55–66
   PubMedGoogle Scholar
• Filiadis I. F., Georgiou I., Alamanos Y., Kranas V., Giannakopoulos X., Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol. 1999; 161: 1672–1675
   PubMed Web of Science ®Google Scholar
• Finley D., Ciechanover A., Varshavsky A. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell 1984; 37: 43–55
   PubMed Web of Science ®Google Scholar
• Frymoyer J. W., Jacox R. F. Studies of genetically controlled sulfadiazine acetylation in rabbit livers: Possible identification of the heterozygous trait. J. Lab. Clin. Med. 1963; 62: 905–909
   PubMed Web of Science ®Google Scholar
• Fullam E., Westwood I. M., Anderton M. C., Lowe E. D., Sim E., Noble M. E. M. Divergence of cofactor recognition across evolution: Coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J. Mol. Biol. 2008; 375: 178–191
   PubMed Web of Science ®Google Scholar
• Glowinski I. B., Weber W. W. Biochemical characterisation of genetically variant aromatic amine N-acetyltransferases in A/J and C57BL/6J mice. J. Biol. Chem. 1982; 257: 1431–1437
   PubMed Web of Science ®Google Scholar
• Goodfellow G. H., Dupret J.-M., Grant D. M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem. J. 2000; 348: 159–166
   PubMed Web of Science ®Google Scholar
• Hein D. W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 2002; 506:507: 65–77
   PubMed Web of Science ®Google Scholar
• Hein D. W., Boukouvala S., Grant D. M., Minchin R. F., Sim E. Changes in consensus arylamine N-acetyltransferase (NAT) gene nomenclature. Pharmacogenet. 2008, in press.
   Google Scholar
• Hein D. W., Doll M. A., Fretland A. J., Leff M. A., Webb S. J., Xiao G. H., Devanaboyina U. S., Nangju N. A., Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 2000; 9: 29–42
   PubMed Web of Science ®Google Scholar
• Hein D. W., Doll M. A., Nerland D. E., Fretland A. J. Tissue distribution of N-acetyltransferase 1 and 2 catalyzing the N-acetylation of 4-aminobiphenyl and O-acetylation of N-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster. Mol. Carcinogen. 2006; 45: 230–238
   PubMed Web of Science ®Google Scholar
• Hein D. W., Doll M. A., Rustan T. D., Gray K., Ferguson R. J., Feng Y. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): Acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol. 1994; 124: 16–24
   PubMed Web of Science ®Google Scholar
• Hein D. W., Neale J. R., Bendaly J., Doll M. A. Construction and initial characterization of Nat2 congenic rat lines. Fourth International Workshop on the Arylamine N-acetyltransferases, AlexandroupolisGreece, 2007
   Google Scholar
• Hein D. W., Omichinski J. G., Brewer J. A., Weber W. W. A unique pharmacogenetic expression of the N-acetylation polymorphism in the inbred hamster. J. Pharmacol. Exper. Ther. 1982; 220: 8–15
   PubMed Web of Science ®Google Scholar
• Hein D. W., Rustan T. D., Bucher K. D., Martin W. J., Furman E. J. Acetylator phenotype-dependent and –independent expression of arylamine N-acetyltransferase isoenzymes in rapid and slow acetylator inbred rat liver. Drug Metab. Dispos. 1991; 19: 933–937
   PubMed Web of Science ®Google Scholar
• Hershko A., Ciechanover A. The ubiquitin system. Ann. Rev. Biochem. 1998; 67: 425–479
   PubMed Web of Science ®Google Scholar
• Hess K. R., Anderson K., Symmans W. F., Valero V., Ibrahim N., Mejia J. A., Booser D., Theriault R. L., Buzdar A. U., Dempsey P. J., Rouzier R., Sneige N., Ross J. S., Vidaurre T., Gómez H. L., Hortobagyi G. N., Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 2006; 24: 4236–4244
   PubMed Web of Science ®Google Scholar
• Hickman D., Pope J., Patil S. D., Fakis G., Smelt V., Stanley L. A., Payton M., Unadkat J. D., Sim E. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998; 42: 402–409
   PubMed Web of Science ®Google Scholar
• Hickman D., Risch A., Buckle V., Spurr N. K., Jeremiah S. J., McCarthy A., Sim E. Chromosomal localisation of human genes for arylamine N-acetyltransferase. Biochem. J. 1994; 297: 441–445
   PubMed Web of Science ®Google Scholar
• Husain A., Barker D. F., States J. C., Doll M. A., Hein D. W. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004; 14: 397–406
   PubMedGoogle Scholar
• Husain A., Zhang X., Doll M. A., States J. C., Barker D. F., Hein D. W. Functional analysis of the human N-acetyltransferase 1 major promoter: Quantitation of tissue expression and identification of critical sequence elements. Drug Metab. Dispos. 2007a; 35: 1649–1656
   PubMed Web of Science ®Google Scholar
• Husain A., Zhang X., Doll M. A., States J. C., Barker D. F., Hein D. W. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab. Dispos. 2007b; 35: 721–727
   PubMed Web of Science ®Google Scholar
• Ivshina A. V., George J., Senko O., Mow B., Putti T.C., Smeds J., Lindahl T., Pawitan Y., Hall P., Nordgren H., Wong J. E., Liu E. T., Bergh J., Kuznetsov V. A., Miller L. D. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006; 66: 10292–10301
   PubMed Web of Science ®Google Scholar
• Jackson P. K., Eldridge A. G., Freed E., Furstenthal L., Hsu J. Y., Kaiser B. K., Reimann J. D. The lord of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell. Biol. 2000; 10: 429–439
   PubMed Web of Science ®Google Scholar
• Jenne J. W. Partial purification and properties of the isoniazid trans-acetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Invest. 1965; 44: 1992–2002
   PubMed Web of Science ®Google Scholar
• Jensen L. E., Hoess K., Mitchell L. E., Whitehead A. S. Loss of function polymorphisms in NAT1 protect against spina bifida. Hum. Genet. 2006; 120: 52–57
   PubMed Web of Science ®Google Scholar
• Jensen L. E., Hoess K., Whitehead A. S., Mitchell L. E. The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. Birth Defects Res. 2005; 73: 512–516
   PubMed Web of Science ®Google Scholar
• Johnston J. A., Illing M. E., Kopito R. R. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil. Cytoskeleton 2002; 53: 26–38
   PubMed Web of Science ®Google Scholar
• Josephy P. D., Evans D. H., Parikh A., Guengerich F. P. Metabolic activation of aromatic amine by simultaneous expression of human cytochrome P450 1A2, NADPH-cytochrome reductase, and N-acetyltransferase in E. coli. Chem. Res. Toxicol. 1998; 11: 70–74
   PubMed Web of Science ®Google Scholar
• Karolyi J., Erickson R. P., Liu S., Killewald L. Major effects on teratogen-induced facial clefting in mice determined by a single genetic region. Genetics 1990; 126: 201–205
   PubMed Web of Science ®Google Scholar
• Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S. A., Vath G. M., Hanna P. E., Wagner C. R., Sim E. Eukaryotic arylamine N-acetyltransferase: Investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 2005; 69: 347–359
   PubMed Web of Science ®Google Scholar
• Kawamura A., Westwood I., Wakefield L., Long H., Zhang N., Walters K., Redfield C., Sim E. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem. Pharmacol. 2008; 75: 1550–1560
   PubMed Web of Science ®Google Scholar
• Kelly S. L., Sim E. Arylamine N-acetyltransferase in Balb/c mice: Identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem. J. 1994; 302: 347–353
   PubMed Web of Science ®Google Scholar
• Kopito R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000; 10: 524–530
   PubMed Web of Science ®Google Scholar
• Lammer E. J., Shaw G. M., Iovannisci D. M., Finnell R. H. Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res. 2004a; 70: 846–852
   PubMed Web of Science ®Google Scholar
• Lammer E. J., Shaw G. M., Iovannisci D. M., Van Waes J., Finnell R. H. Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology 2004b; 15: 150–156
   PubMed Web of Science ®Google Scholar
• Land S. J., Jones R. E., King C. M. Biochemical and genetic analysis of two acetyltransferases from hamster tissues that can metabolise aromatic amine derivatives. Carcinogenesis 1994; 15: 1585–1595
   PubMed Web of Science ®Google Scholar
• Lee J. H., Chung J. G., Lai J. M., Levy G. N., Weber W. W. Kinetics of arylamine N-acetyltransferase in tissues from human breast cancer. Cancer Lett. 1997; 111: 39–50
   PubMed Web of Science ®Google Scholar
• Levy G. N., Martell K. J., DeLeon J. H., Weber W. W. Metabolic, molecular genetic and toxicological aspects of the acetylation polymorphism in inbred mice. Pharmacogenetics 1992; 2: 197–206
   PubMedGoogle Scholar
• Lissowska J., Brinton L. A., Zatonski W., Blair A., Bardin-Mikolajczak A., Peplonska B., Sherman M. E., Szeszenia-Dabrowska N., Chanock S., García-Closas M. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int. J. Cancer 2006; 119: 1961–1969
   PubMed Web of Science ®Google Scholar
• Liu F., Zhang N., Zhou X., Hanna P. E., Wagner C. R., Koepp D. M., Walters K. J. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol. 2006; 361: 482–492
   PubMed Web of Science ®Google Scholar
• Loehle J. A., Cornish V., Wakefield L., Doll M. A., Neale J. R., Zang Y., Sim E., Hein D. W. N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J. Pharmacol. Exper. Ther. 2006; 319: 724–728
   PubMed Web of Science ®Google Scholar
• Lower G. M., Jr., Nilsson T., Nelson C. E., Wolf H., Gamsky T. E., Bryan G. T. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 1979; 29: 71–79
   PubMed Web of Science ®Google Scholar
• Magalon H., Patin E., Austerlitz F., Hegay T., Aldashev A., Quintana-Murci L., Heyer E. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur. J. Hum. Genet. 2008; 16: 243–251
   PubMed Web of Science ®Google Scholar
• Major G. N., Brady M., Notarianni G. B., Collier J. D., Douglas M. S. Evidence for ubiquitin-mediated degradation of the DNA repair enzyme for O6-methylguanine in non-tumour derived human cell and tissue extracts. Biochem. Soc. Trans. 1997; 25: 359S
   PubMed Web of Science ®Google Scholar
• Martell K. J., Vatsis K. P., Weber W. W. Molecular genetic basis of rapid and slow acetylation in mice. Mol. Pharmacol. 1991; 40: 218–227
   PubMed Web of Science ®Google Scholar
• Mattano S. S., Erickson R. P., Nesbitt M. N., Weber W. W. Linkage of Nat and Es-1 in the mouse and development of strains congenic for N-acetyltransferase. J. Hered. 1988; 79: 430–433
   PubMed Web of Science ®Google Scholar
• McClellan A. J., Scott M. D., Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 2005; 121: 739–748
   PubMed Web of Science ®Google Scholar
• Miller L. D., Smeds J., George J., Vega V. B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E. T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005; 102: 13550–13555
   PubMed Web of Science ®Google Scholar
• Minchin R. F. Acetylation of p-amino benzoylglutamate, a folic acid catabolite, by recombinant arylamine N-acetyltransferase and U937 cells. Biochem. J. 1995; 307: 1–3
   PubMed Web of Science ®Google Scholar
• Minchin R. F., Hanna P. E., Dupret J. M., Wagner C. R., Rodrigues-Lima F., Butcher N. J. Molecules in focus: Arylamine N-acetyltransferase I. Int. J. Biochem. Cell Biol. 2007a; 39: 1999–2005
   PubMed Web of Science ®Google Scholar
• Minchin R. F., Tiang J., Butcher N. J. The effect of down-regulation and up-regulation of arylamine N-acetyltransferase-1 on cell growth and survival. Fourth International Workshop on the Arylamine N-acetyltransferases, AlexandroupolisGreece, 2007b
   Google Scholar
• Mitchell M. K., Futscher B. W., McQueen C. A. Developmental expression of N-acetyltransferases in C57Bl/6 mice. Drug Metab. Dispos. 1999; 27: 26–264
   PubMed Web of Science ®Google Scholar
• Muller S., Hoege C., Pyrowolakis G., Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2001; 2: 202–210
   PubMed Web of Science ®Google Scholar
• Muratani M., Tansey W. P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 2003; 4: 192–201
   PubMed Web of Science ®Google Scholar
• Mushtaq A., Payton M., Sim E. The COOH terminus of arylamine N-acetyltransferase for Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 2002; 277: 12175–12181
   PubMed Web of Science ®Google Scholar
• Nakura H., Itoh S., Kusano H., Ishizone H., Deguchi T., Kamataki T. Evidence for the lack of hepatic N-acetyltransferases in suncus (Suncus marinus). Biochem. Pharm. 1995; 50: 1165–1170
   PubMed Web of Science ®Google Scholar
• Ochs-Balcom H. M., Wiesner G., Elston R. C. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am. J. Epidemiol. 2007; 166: 246–254
   PubMed Web of Science ®Google Scholar
• Okkels H., Sigsgaard T., Wolf H., Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 225–231
   PubMed Web of Science ®Google Scholar
• Oldenburg R. A., Meijers-Heijboer H., Cornelisse C. J., Devilee P. Genetic susceptibility for breast cancer: How many more genes to be found?. Crit. Rev. Oncol. Hematol. 2007; 63: 125–149
   PubMed Web of Science ®Google Scholar
• Pacifici G. M., Bencini C., Rane A. Acetyltransferase in humans: Development and tissue distribution. Pharmacol. 1986; 32: 283–291
   PubMed Web of Science ®Google Scholar
• Patin E., Barreiro L. B., Sabeti P. C., Austerlitz A., Luca F., Sajantila A., Behar D. M., Semino O., Sakuntabhai A., Guiso N., Gicquel B., McElreavey K., Harding R. M., Heyer E., Quintana-Murci L. Deciphering the ancient and complex evolutionary history of human arylamine n-acetyltransferase genes. Am. J. Hum. Genet. 2006; 78: 423–436
   PubMed Web of Science ®Google Scholar
• Payton M., Auty R., Delgoda R., Everett M., Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and M. tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. 1999a; 181: 1343–1347
   PubMed Web of Science ®Google Scholar
• Payton M., Gifford C., Schartau P., Hagemeier C., Mushtaq A., Lucas S., Pinter K., Sim E. Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of. Mycobacterium tuberculosis. Microbiol. 2001a; 147: 3295–3302
   Google Scholar
• Payton M., Mushtaq A., Yu T., Wu L., Sinclair J., Sim E. Eubacterial arylamine N-acetyltransferases-identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiol. 2001b; 147: 1137–1147
   PubMed Web of Science ®Google Scholar
• Payton M., Smelt V., Upton A., Sim E. A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): A gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem. Pharmacol. 1999b; 58: 779–785
   PubMed Web of Science ®Google Scholar
• Pegg A. E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 2000; 462: 83–100
   PubMed Web of Science ®Google Scholar
• Pfau W., Stone E. M., Brockstedt U., Carmichael P.L., Marquardt H., Phillips D. H. DNA adducts in human breast tissue: Association with N-acetyltransferase-2 (NAT2) and NAT1 genotypes. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 1019–1025
   PubMed Web of Science ®Google Scholar
• Pompeo F., Brooke E. W., Kawamura A., Mushtaq A., Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 2002; 3: 19–30
   PubMed Web of Science ®Google Scholar
• Rasimas J. J., Dalessio P. A., Ropson I. J., Pegg A. E., Fried M. G. Active-site alkylation destabilizes human O6-alkylguanine DNA alkyltransferase. Protein Sci. 2004; 13: 301–305
   PubMed Web of Science ®Google Scholar
• Rhodes D. R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A. M. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1–6
   PubMed Web of Science ®Google Scholar
• Riddle B., Jencks W. P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 1971; 246: 3250–3258
   PubMed Web of Science ®Google Scholar
• Risch A., Wallace D. M. A., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 1995; 4: 231–236
   PubMed Web of Science ®Google Scholar
• Rock K. L., Goldberg A. L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Ann. Rev. Immunol. 1999; 17: 739–779
   PubMed Web of Science ®Google Scholar
• Sakahira H., Breuer P., Hayer-Hartl M. K., Hartl F. U. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl. Acad. Sci. USA 2002; 99(Suppl 4)16412–16418
   PubMed Web of Science ®Google Scholar
• Sandy J., Mushtaq A., Holton S. J., Schartau P., Noble M. E. M., Sim E. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyltransfer to arylamines. Biochem. J. 2005; 390: 115–123
   PubMed Web of Science ®Google Scholar
• Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis – an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 2002; 318: 1071–1083
   PubMed Web of Science ®Google Scholar
• Sasaki Y., Ohsako S., Deguchi T. Molecular and genetic analysis of arylamine N-acetyltransferase of rabbit liver. J. Biol. Chem. 1991; 266: 13243–13250
   PubMed Web of Science ®Google Scholar
• Scheffner M., Staub O. HECT E3s and human disease. BMC Biochem. 2007; 8(Suppl 1)S6
   PubMed Web of Science ®Google Scholar
• Schubert U., Anton L. C., Gibbs J., Norbury C. C., Yewdell J. W., Bennink J. R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404: 770–774
   PubMed Web of Science ®Google Scholar
• Sheaff R. J., Groudine M., Gordon M., Roberts J. M., Clurman B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997; 11: 1464–1478
   PubMed Web of Science ®Google Scholar
• Shi M., Christensen K., Weinberg C. R., Romitti P., Bathum L., Lozada A., Morris R. W., Lovett M., Murray J. C. Orofacial cleft risk is increased with maternal smoking and specific detoxification-specific variants. Am. J. Hum. Genet. 2007; 80: 76–90
   PubMed Web of Science ®Google Scholar
• Sholto-Douglas-Vernon C., Sandy J., Victor T. C., Sim E., van Helden P. D. Mutational and expression analysis of tbnat and its response to isoniazid. J. Med. Microbiol. 2005; 54: 1189–1197
   PubMed Web of Science ®Google Scholar
• Sim E., Westwood I., Fullam E. Arylamine N-acetyltransferases. Expert Opin. Drug. Metab. Toxicol. 2007; 3: 169–184
   PubMed Web of Science ®Google Scholar
• Sinclair J., Sim E. A fragment consisting of the first 204 amino terminal residues of arylamine N-acetyltransferase is active in the first acetylation step of catalysis. Biochem. Pharm. 1997; 53: 11–16
   PubMed Web of Science ®Google Scholar
• Sinclair J. C., Sandy J., Delgoda R., Sim E., Noble M. E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 2000; 7: 560–564
   PubMedGoogle Scholar
• Smelt V. A., Mardon H. J., Sim E. Placental expression of arylamine N-acetyltransferases: Evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol. Toxicol. 1998; 83: 149–157
   PubMedGoogle Scholar
• Smelt V. A., Upton A., Adjaye J., Payton M. A., Boukouvala S., Johnson N., Mardon H. J., Sim E. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum. Mol. Genet. 2000; 9: 1101–1107
   PubMed Web of Science ®Google Scholar
• Smolen T. N., Brewer J. A., Weber W. W. Testosterone modulation of N-acetylation in mouse kidney. J. Pharmacol. Exper. Ther. 1993; 264: 854–858
   PubMed Web of Science ®Google Scholar
• Sørlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J.C., Brown P. O., Botstein D., Eystein Lønning P., Børresen-Dale A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001; 98: 10869–10874
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M. J., Bergh J., Piccart M., Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006; 98: 262–272
   PubMed Web of Science ®Google Scholar
• Srivenugopal K. S., Yuan X. H., Friedman H. S., Ali-Osman F. Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Bio-chemistry 1996; 35: 1328–1334
   Google Scholar
• Stanley L. A., Copp A. J., Pope J., Rolls S., Smelt V., Perry V. H., Sim E. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 1998; 58: 174–182
   PubMedGoogle Scholar
• Stanley L. A., Mills I. G., Sim E. Localisation of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics 1997; 7: 121–130
   PubMedGoogle Scholar
• Sugamori K. S., Brenneman D., Grant D. M. In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. Drug Metab. Dispos. 2006; 34: 1697–1702
   PubMed Web of Science ®Google Scholar
• Sugamori K. S., Wong S., Gaedigk A., Yu V., Abramovici H., Rozmahel R., Grant D. M. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol. Pharmacol. 2003; 64: 170–179
   PubMed Web of Science ®Google Scholar
• Terry P. D., Goodman M. Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 602–611
   PubMed Web of Science ®Google Scholar
• Trepanier L. A., Cribb A., Spielberg S. P., Ray K. Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene. Pharmacogenetics 1998; 8: 169–179
   PubMedGoogle Scholar
• Trepanier L. A., Ray K., Winand N. J., Spielberg S. P., Cribb A. E. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem. Pharmacol. 1997; 54: 73–80
   PubMed Web of Science ®Google Scholar
• Upton A., Everett M., Mushtaq A., van Helden P., Victor T., Wagner R., Sim E. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of metabolism of isoniazid. Mol. Microbiol. 2001; 42: 309–319
   PubMed Web of Science ®Google Scholar
• Upton A., Smelt V., Mushtaq A., Aplin R., Johnson N., Mardon H., Sim E. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim. Biophys. Acta 2000; 1524: 143–148
   PubMed Web of Science ®Google Scholar
• Van der Geize R., Heuser T., Yam K., Wilbrink M. H., Hara H., Anderton M.C., Sim E., Dijkuizen L., Davies J. E., Mohn W. W., Eltis L. D. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. USA 2007; 104: 1947–1952
   PubMed Web of Science ®Google Scholar
• van't Veer L. J., Dai H., van de Vijver M. J., He Y. D., Hart A. A., Mao M., Peterse H. L., van der Kooy K., Marton M. J., Witteveen A. T., Schreiber G. J., Kerkhoven R. M., Roberts C., Linsley P. S., Bernards R., Friend S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–536
   PubMed Web of Science ®Google Scholar
• Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997; 16: 5334–5344
   PubMed Web of Science ®Google Scholar
• Wakefield L., Cornish V., Broackes-Carter F., Sim E. Arylamine N-acetyltransferase 2 expression in the developing heart. J. Histochem. Cytochem. 2005; 53: 583–592
   PubMed Web of Science ®Google Scholar
• Wakefield L., Cornish V., Long H., Griffiths W. J., Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem. Biophys. Res. Commun. 2007a; 364: 556–560
   PubMed Web of Science ®Google Scholar
• Wakefield L., Cornish V., Long H., Kawamura A., Zhang X., Hein D. W., Sim E. Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: A potential marker for the developing neuroendocrine system. Biomarkers 2008a; 13: 106–118
   PubMed Web of Science ®Google Scholar
• Wakefield L., Long H., Lack N., Sim E. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene. Mamm. Genome 2007b; 18(4)270–276
   PubMed Web of Science ®Google Scholar
• Wakefield L., Robinson J., Long H., Ibbit J. C., Cooke S., Hurst H. C., Sim E. Arylamine N-acetyltransferase I expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 2008b; 47: 118–126
   PubMed Web of Science ®Google Scholar
• Walraven J. M., Barker D. F., Doll M. A., Hein D. W. Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and functional characterization of a novel rNat3*2 genetic variant. Toxicol. Sci. 2007a; 99: 413–421
   PubMed Web of Science ®Google Scholar
• Walraven J. M., Doll M. A., Hein D. W. Identification and characterization of functional rat arylamine N-acetyltransferase 3: Comparisons with rat arylamine N-acetyltransferases 1 and 2. J. Pharmacol. Exp. Ther. 2006; 319: 369–375
   PubMed Web of Science ®Google Scholar
• Walraven J. M., Trent J. O., Hein D. W. Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metab. Dispos. 2007b; 35: 1001–1007
   PubMed Web of Science ®Google Scholar
• Wang L., Nguyen T. V., McLaughlin R. W., Sikkink L. A., Ramirez-Alvarado M., Weinshilboum R. M. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl. Acad. Sci. USA 2005; 102: 9394–9399
   PubMed Web of Science ®Google Scholar
• Ward A., Summers M. J., Sim E. Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterisation of its potential role in folate metabolism. Biochem. Pharmacol. 1995; 49: 1759–1767
   PubMed Web of Science ®Google Scholar
• Watanabe M., Sofuni T., Nohmi T. Involvement of Cys69 residue in the catalytic mechanism of N-hydroxylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferases for S. typhimurium and higher organisms. J. Biol. Chem. 1992; 267: 8429–8436
   PubMed Web of Science ®Google Scholar
• Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol. Rev. 1985; 37: 25–79
   PubMed Web of Science ®Google Scholar
• Westwood I. M., Kawamura A., Fullam E., Russell A. J., Davies S. G., Sim E. Structure and Mechanism of Arylamine N-acetyltransferases. Curr. Top. Med. Chem. 2006; 6: 1641–1654
   PubMed Web of Science ®Google Scholar
• Williams J. A., Stone A. M., Fakis G., Johnson N., Cordell J. A., Meinl W., Glatt H., Sim E., Phillips D. H. N-acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics 2001; 11: 371–388
   Google Scholar
• Wu H., Dombrovsky L., Tempel W., Martin F., Loppnau P., Goodfellow G. H., Grant D. M., Plotnikov A. N. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J. Biol. Chem. 2007; 282: 30189–30197
   PubMed Web of Science ®Google Scholar
• Xu-Welliver M., Pegg A. E. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis 2002; 23: 823–830
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R., Sachrowardi Q., Nishida N., Takasu M., Batubara L., Susmiarsih T. P., Rochani J. T., Wikaningrum R., Miyashita R., Miyagawa T., Sofro A. S., Tokunaga K. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J. Hum. Genet. 2008, in press.
   PubMed Web of Science ®Google Scholar
• Zang Y., Zhao S., Doll M. A., States J. C., Hein D. W. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 2004; 14: 717–723
   PubMedGoogle Scholar
• Zhang N., Liu L., Liu F., Wagner C. R., Hanna P. E., Walters K. J. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol. 2006; 363: 188–200
   PubMed Web of Science ®Google Scholar